Branded Specialty Products

About Bora Pharmaceuticals

Bora Pharmaceuticals has established itself as a premier hybrid CDMO and pharmaceutical developer in Asia, achieving significant scale with a market capitalization exceeding $57 billion. The company's strategy successfully integrates high-margin contract services with proprietary drug development, creating a diversified and resilient revenue model. Its core achievements include building PIC/S and FDA-compliant manufacturing facilities, developing a robust pipeline of complex generics and specialty products, and securing a strong position as a critical supply chain partner for multinational pharmaceutical companies.

Therapeutic Areas